Two reverse-transcription reactions were performed for each sample using either 100 or 25 ng of input RNA
The orientation table below is unpacked, with citations, in the sections that follow
Our lead clinical programs drug candidate, VK2735, is being developed in both oral and subcutaneous formulations for the potential treatment of various metabolic disorders such as obesity
These limitations have motivated researchers to investigate alternative delivery methods that can bypass the BBB while ensuring sufficient patient compliance, preferably avoiding invasive routes like injections
Then there is the rebound. The data suggests that when patients stop the drug, the weight often returns if lifestyle changes were not solidified
When you do this, you have no idea whats actually working